Kumar N, Papillon-Cavanagh S, Tang H, Wang S, Stromko C, Ho CP, Soni-Sheth S, Vasquez-Grinnell S, Broz ML, Tenney DJ, Wichroski MJ, Walsh AM, Hu Y, Benci JL.,
A multi‐omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti‐PD1 response in solid tumors, Int J Cancer. 2022 Dec 1;151(11):2043-2054. doi: 10.1002/ijc.34218.
Feola S, Chiaro J, Martins B, Russo S, Fusciello M, Ylösmäki E, Bonini C, Ruggiero E, Hamdan F, Feodoroff M, Antignani G, Viitala T, Pesonen S, Grönholm M, Branca RMM, Lehtiö J, Cerullo V.,
A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines, Elife. 2022 Mar 22;11:e71156. doi: 10.7554/eLife.71156.
Bordat A, Boissenot T, Ibrahim N, Ferrere M, Levêque M, Potiron L, Denis S, Garcia-Argote S, Carvalho O, Abadie J, Cailleau C, Pieters G, Tsapis N, Nicolas J.,
A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs, J Am Chem Soc. 2022 Oct 19;144(41):18844-18860. doi: 10.1021/jacs.2c04944. Epub 2022 Oct 4.
Gomes AP, Ilter D, Low V, Drapela S, Schild T, Mullarky E, Han J, Elia I, Broekaert D, Rosenzweig A, Nagiec M, Nunes JB, Schaffer BE, Mutvei AP, Asara JM, Cantley LC, Fendt SM, Blenis J.,
Altered propionate metabolism contributes to tumour progression and aggressiveness, Nat Metab. 2022 Apr;4(4):435-443. doi: 10.1038/s42255-022-00553-5. Epub 2022 Mar 31.
Forte, B. L., Slosky, L. M., Zhang, H., Arnold, M. R., Staatz, W. D., Hay, M., . . . Vanderah, T. W. (2016).,
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain., Pain, 157(12), 2709-2721. doi:10.1097/j.pain.0000000000000690 [doi]
Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, Chiang SC, Chikkanna-Gowda CP, Rogers N, Silva-Santos B, Jaillon S, Mantovani A, Reis E Sousa C, Guerra N, Davis DM, Zelenay S.,
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade, Immunity. 2020 Dec 15;53(6):1215-1229.e8. doi: 10.1016/j.immuni.2020.10.020. Epub 2020 Nov 20.
Nastasi N, Pasha A, Bruno G, Subbiani A, Pietrovito L, Leo A, Scala L, de Simone L, Casazza G, Lunardi F, Taddei ML, Tamburini A, Tondo A, Favre C, Calvani M.,
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma., Cancers (Basel). 2023 Sep 27;15(19). pii: 4744. doi: 10.3390/cancers15194744.
Benguigui M, Vorontsova A, Timaner M, Levin S, Haj-Shomaly J, Deo A, Menachem R, Manobla B, Cooper TJ, Raviv Z, Shaked Y.,
Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors, Front Immunol. 2022 Jul 7;13:903591. doi: 10.3389/fimmu.2022.903591
Petruk N, Tuominen S, Åkerfelt M, Mattsson J, Sandholm J, Nees M, Yegutkin GG, Jukkola A, Tuomela J, Selander KS.,
CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer., Sci Rep. 2021 Mar 16;11(1):6035. doi: 10.1038/s41598-021-85379-z.
Arroyo-Crespo, Juan J; Armiñán, Ana; Charbonnier, David; Deladriere, Coralie; Palomino-Schätzlein, Martina; Lamas-Domingo, Rubén; Forteza, Jerónimo; Pineda-Lucena, Antonio; Vicent, María,
Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression., International journal of cancer Vol.145, 2019
Baram T, Erlichman N, Dadiani M, Balint-Lahat N, Pavlovski A, Meshel T, Morzaev-Sulzbach D, Gal-Yam EN, Barshack I, Ben-Baruch A.,
Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors., Cells. 2021 Jun 8;10(6). pii: 1429. doi: 10.3390/cells10061429.
Patel SS, Hoogenboezem EN, Yu F, DeJulius CR, Fletcher RB, Sorets AG, Cherry FK, Lo JH, Bezold MG, Francini N, d'Arcy R, Brasuell JE, Cook RS, Duvall CL.,
Core polymer optimization of ternary siRNA nanoparticles enhances in vivo safety, pharmacokinetics, and tumor gene silencing., Biomaterials. 2023 Jun;297:122098. doi: 10.1016/j.biomaterials.2023.122098. Epub 2023 Mar 28.
Teijeira Á, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvisé M, Rouzaut A, Sanmamed MF, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I.,
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity, Immunity. 2020 May 19;52(5):856-871.e8. doi: 10.1016/j.immuni.2020.03.001. Epub 2020 Apr 13.
Falvo P, Orecchioni S, Hillje R, Raveane A, Mancuso P, Camisaschi C, Luzi L, Pelicci P, Bertolini F.,
Cyclophosphamide and Vinorelbine Activate Stem-Like CD8(+) T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer., Cancer Res. 2021 Feb 1;81(3):685-697. doi: 10.1158/0008-5472.CAN-20-1818. Epub 2020 Dec 2. Erratum in: Cancer Res. 2021 Jun 15;81(12):3426.
Falvo P, Orecchioni S, Hillje R, Raveane A, Mancuso P, Camisaschi C, Luzi L, Pelicci P, Bertolini F.,
Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer, Cancer Res. 2020 Dec 2:canres.1818.2020. doi: 10.1158/0008-5472.CAN-20-1818. Online ahead of print.
Wang C, Barnoud C, Cenerenti M, Sun M, Caffa I, Kizil B, Bill R, Liu Y, Pick R, Garnier L, Gkountidi OA, Ince LM, Holtkamp S, Fournier N, Michielin O, Speiser DE, Hugues S, Nencioni A, Pittet MJ, Jandus C, Scheiermann C.,
Dendritic cells direct circadian anti-tumour immune responses., Nature. 2023 Feb;614(7946):136-143. doi: 10.1038/s41586-022-05605-0. Epub 2022 Dec 5.
Kol A, Fan X, Wazynska MA, van Duijnhoven SMJ, Giesen D, Plat A, Van Eenennaam H, Elsinga PH, Nijman HW, de Bruyn M.,
Development of (89)Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration, J Immunother Cancer. 2022 Dec;10(12):e004877. doi: 10.1136/jitc-2022-004877.
Fan X, Ważyńska MA, Kol A, Perujo Holland N, Fernandes B, van Duijnhoven SMJ, Plat A, van Eenennaam H, Elsinga PH, Nijman HW, de Bruyn M.,
Development of [(89)Zr]Zr-hCD103.Fab01A and [(68)Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET., EJNMMI Res. 2023 Nov 20;13(1):100. doi: 10.1186/s13550-023-01043-9.
Chiaro, J., Antignani, G., Feola, S., Feodoroff, M., Martins, B., Cojoc, H., Russo, S., Fusciello, M., Hamdan, F., Ferrari, V., Ciampi, D., Ilonen, I., Räsänen, J., Mäyränpää, M., Partanen, J., Koskela, S., Honkanen, J., Halonen, J., Kuryk, L., Rescigno, M., … Cerullo, V.,
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors., Nat Commun. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7.
Gu Z, Da Silva CG, Hao Y, Schomann T, Camps MGM, van der Maaden K, Liu Q, Ossendorp F, Cruz LJ.,
Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer, J Control Release. 2022 Dec 9;353:490-506. doi: 10.1016/j.jconrel.2022.11.049.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP.,
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma., iScience. 2021 Jun 19;24(7):102759. doi: 10.1016/j.isci.2021.102759. eCollection 2021 Jul 23.
Jang SC, Economides KD, Moniz RJ, Sia CL, Lewis N, McCoy C, Zi T, Zhang K, Harrison RA, Lim J, Dey J, Grenley M, Kirwin K, Ross NL, Bourdeau R, Villiger-Oberbek A, Estes S, Xu K, Sanchez-Salazar J, Dooley K, Dahlberg WK, Williams DE, et al.,
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance., Commun Biol. 2021 Apr 22;4(1):497. doi: 10.1038/s42003-021-02004-5.
Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Turner JBM, Gigliotti PJ, Kraskauskiene V, Shende M, Idowu MO, Puchalapalli M, Hu B, Litovchick L, Katsuta E, Takabe K, Farrell NP, Koblinski JE.,
Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer, Mol Cancer Ther. 2022 Feb;21(2):271-281. doi: 10.1158/1535-7163.MCT-20-0969
van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, Wong TJ, Denisov SS, Hackeng TM, Jimenez CR, Nowak-Sliwinska P, Griffioen AW.,
Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy, Nat Commun. 2022 May 23;13(1):2842. doi: 10.1038/s41467-022-30063-7.
Karimaa M, Riikonen R, Kettunen H, Taavitsainen P, Ramela M, Chrusciel M, Karlsson S, Rummakko P, Simola O, Wohlfahrt G, Hakulinen P, Vuorela A, Joensuu H, Utriainen T, Fizazi K, Oksala R.,
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis, Mol Cancer Ther. 2022 Dec 2;21(12):1765-1776. doi: 10.1158/1535-7163.MCT-22-0115.
Suurs FV, Qiu SQ, Yim JJ, Schröder CP, Timmer-Bosscha H, Bensen ES, Santini JT Jr, de Vries EGE, Bogyo M, van Dam GM.,
Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model, EJNMMI Res. 2020 Sep 29;10(1):111. doi: 10.1186/s13550-020-00688-0.
Huang CH, Dong T, Phung AT, Shah JR, Larson C, Sanchez AB, Blair SL, Oronsky B, Trogler WC, Reid T, Kummel AC.,
Full Remission of CAR-Deficient Tumors by DOTAP-Folate Liposome Encapsulation of Adenovirus, ACS Biomater Sci Eng. 2022 Dec 12;8(12):5199-5209. doi: 10.1021/acsbiomaterials.2c00966. Epub 2022 Nov 17.
Rivera-Huerta, M., Lizarraga-Grimes, V. L., Castro-Torres, I. G., Tinoco-Mendez, M., Macias-Rosales, L., Sanchez-Bartez, F., . . . Gracia-Mora, M. I. (2017).,
Functional effects of prebiotic fructans in colon cancer and calcium metabolism in animal models., BioMed Research International, 2017, 9758982. doi:10.1155/2017/9758982 [doi]
Nie P, Kalidindi T, Nagle VL, Wu X, Li T, Liao GP, Frost G, Henry KE, Punzalan B, Carter LM, Lewis JS, Pillarsetty NVK, Li YM.,
Imaging of Cancer Îł-Secretase Activity Using an Inhibitor-Based PET Probe., Clin Cancer Res. 2021 Nov 15;27(22):6145-6155. doi: 10.1158/1078-0432.CCR-21-0940. Epub 2021 Sep 2.
Alsaid H, Cheng SH, Bi M, Xie F, Rambo M, Skedzielewski T, Hoang B, Mohanan S, Comroe D, Gehman A, Hsu CY, Farhangi K, Tran H, Sherina V, Doan M, Groseclose MR, Hopson CB, Brett S, Wilson IA, Nicholls A, Ballas M, Waight JD, Jucker BM.,
Immuno-PET Monitoring of CD8(+) T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a (89)Zr Anti-CD8(+) Mouse Minibody in EMT6 Syngeneic Tumor Mouse, Mol Imaging Biol. 2022 Oct 20. doi: 10.1007/s11307-022-01781-7. Online ahead of print.
Alsaid H, Cheng SH, Bi M, Xie F, Rambo M, Skedzielewski T, Hoang B, Mohanan S, Comroe D, Gehman A, Hsu CY, Farhangi K, Tran H, Sherina V, Doan M, Groseclose MR, Hopson CB, Brett S, Wilson IA, Nicholls A, Ballas M, Waight JD, et al.,
Immuno-PET Monitoring of CD8(+) T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a (89)Zr Anti-CD8(+) Mouse Minibody in EMT6 Syngeneic Tumor Mouse., Mol Imaging Biol. 2023 Jun;25(3):528-540. doi: 10.1007/s11307-022-01781-7. Epub 2022 Oct 20.
Sanchez-Gonzalez, B., Garcia-Vazquez, F. J., Farfan-Morales, J. E., & Jimenez-Zamudio, L. A. (2015).,
Increased NHC cells in the peritoneal cavity of plasmacytoma susceptible BALB/c mouse., Mediators of Inflammation, 2015, 313140. doi:10.1155/2015/313140 [doi]
Confino H, Sela Y, Epshtein Y, Malka L, Goldshtein M, Chaisson S, Lisi S, Avniel A, Monson JM, Dirbas FM.,
Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice., Cells. 2023 Oct 11;12(20). pii: 2439. doi: 10.3390/cells12202439.
Suurs FV, Lorenczewski G, Bailis JM, Stienen S, Friedrich M, Lee F, van der Vegt B, de Vries EGE, de Groot DA, Lub-de Hooge MN.,
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues., J Nucl Med. 2021 Apr 30. pii: jnumed.120.259036. doi: 10.2967/jnumed.120.259036. [Epub ahead of print]
Alessandri, Giulio; Coccè, Valentina; Pastorino, Fabio; Paroni, Rita; Dei Cas, Michele; Restelli, Francesco; Pollo, Bianca; Gatti, Laura; Tremolada, Carlo; Berenzi, Angiola; Parati, Eugenio; Brini, Anna Teresa; Bondiolotti, Gianpietro; Ponzoni, Mirco; Pessina, Augusto,
Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapy., Journal of controlled release : official journal of the Controlled Release Society Vol.302, 2019
Watters CR, Barro O, Elliott NM, Zhou Y, Gabere M, Raupach E, Baker AT, Barrett MT, Buetow KH, Jacobs B, Seetharam M, Borad MJ, Nagalo BM.,
Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma., Mol Ther Oncolytics. 2023 Mar 1;29:4-14. doi: 10.1016/j.omto.2023.02.009. eCollection 2023 Jun 15.
Bach-Griera M, Campo-Pérez V, Barbosa S, Traserra S, Guallar-Garrido S, Moya-Andérico L, Herrero-Abadía P, Luquin M, Rabanal RM, Torrents E, Julián E.,
Mycolicibacterium brumae Is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment, Vaccines (Basel). 2020 Apr 25;8(2):198. doi: 10.3390/vaccines8020198.
Perez-Lanzon M, Carbonnier V, Cordier P, De Palma FDE, Petrazzuolo A, Klein C, Arbaretaz F, Mangane K, Stoll G, Martins I, Fohrer Ting H, Paillet J, Mouillet-Richard S, Le Corre D, Xiao W, Sroussi M, Desdouets C, Laurent-Puig P, Pol J, Lopez-Otin C, Maiuri MC, Kroemer G.,
New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma., J Immunother Cancer. 2023 Jun;11(6). pii: e007117. doi: 10.1136/jitc-2023-007117.
Lusche DF, Wessels DJ, Reis RJ, Forrest CC, Thumann AR, Soll DR.,
New monoclonal antibodies that recognize an unglycosylated, conserved, extracellular region of CD44 in vitro and in vivo, and can block tumorigenesis., PLoS One. 2021 Apr 23;16(4):e0250175. doi: 10.1371/journal.pone.0250175. eCollection 2021.
Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L, Gomez H, Isaacs C, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Pietenpol JA, Balko JM.,
NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer., Cancer Discov. 2023 Oct 4. doi: 10.1158/2159-8290.CD-23-0519. [Epub ahead of print]
Smith AJ, Thurman RE, Zeng W, Grogan B, Lucas S, Gutierrez G, Heiser RA, Wo SW, Blackmarr A, Peterson S, Gardai SJ.,
Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity., Front Immunol. 2023 Nov 1;14:1280986. doi: 10.3389/fimmu.2023.1280986. eCollection 2023.
Raineri D, Dianzani C, Cappellano G, Maione F, Baldanzi G, Iacobucci I, Clemente N, Baldone G, Boggio E, Gigliotti CL, Boldorini R, Rojo JM, Monti M, Birolo L, Dianzani U, Chiocchetti A.,
Osteopontin binds ICOSL promoting tumor metastasis, Commun Biol. 2020 Oct 26;3(1):615. doi: 10.1038/s42003-020-01333-1.
Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, Speicher DW, Zhang Q, Donthireddy LR, Mostafa A, Tsyganova S, Pisarev V, Laufer T, Ignatov D, Ferrone S, Meyer C, Maby-El Hajjami H, Speiser DE, Altiok S, Antonia S, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Yuan Z, Montaner LJ, Celis E, Gabrilovich DI.,
Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy, Cancer Cell. 2022 Oct 10;40(10):1173-1189.e6.
Ursic K, Kos S, Kamensek U, Cemazar M, Miceska S, Markelc B, Bucek S, Staresinic B, Kloboves Prevodnik V, Heller R, Sersa G.,
Potentiation of electrochemotherapy effectiveness by immunostimulation with IL-12 gene electrotransfer in mice is dependent on tumor immune status., J Control Release. 2021 Apr 10;332:623-635. doi: 10.1016/j.jconrel.2021.03.009. Epub 2021 Mar 8.
Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD.,
Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors, Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455
Larrouqučre L, Berthier S, Chovelon B, Garrel C, Vacchina V, Paucot H, Boutonnat J, Faure P, Hazane-Puch F.,
Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells., Int J Mol Sci. 2021 Sep 30;22(19). pii: 10646. doi: 10.3390/ijms221910646.
Kandasamy M, Gileadi U, Rijal P, Tan TK, Lee LN, Chen J, Prota G, Klenerman P, Townsend A, Cerundolo V.,
Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors, Elife. 2023 Jan 10;12:e76414. doi: 10.7554/eLife.76414.
Hezkiy EE, Kumar S, Gahramanov V, Yaglom J, Hesin A, Jadhav SS, Guzev E, Patel S, Avinery E, Firer MA, Sherman MY.,
Search for Synergistic Drug Combinations to Treat Chronic Lymphocytic Leukemia, Cells. 2022 Nov 18;11(22):3671. doi: 10.3390/cells11223671
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, et al.,
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models., J Immunother Cancer. 2023 Oct;11(10). pii: e007572. doi: 10.1136/jitc-2023-007572.
Kastner A, Mendrina T, Babu T, Karmakar S, Poetsch I, Berger W, Keppler BK, Gibson D, Heffeter P, Kowol CR.,
Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs., Inorg Chem Front. 2023 Dec 6;11(2):534-548. doi: 10.1039/d3qi02032k. eCollection 2024 Jan 16.
Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, Brandhorst S, Curigliano G, Nencioni A, de Braud F, Longo VD.,
Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers, Nat Commun. 2020 May 11;11(1):2332. doi: 10.1038/s41467-020-16243-3.
Ren W, Deng Y, Ward JD, Vairin R, Bai R, Wanniarachchi HI, Hamal KB, Tankoano PE, Tamminga CS, Bueno LMA, Hamel E, Mason RP, Trawick ML, Pinney KG.,
Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization., Eur J Med Chem. 2024 Jan 5;263:115794. doi: 10.1016/j.ejmech.2023.115794. Epub 2023 Sep 6.
Happl B, Brandt M, Balber T, BenÄurov¡ K, Talip Z, Voegele A, Heffeter P, Kandioller W, Van der Meulen NP, Mitterhauser M, Hacker M, Keppler BK, Mindt TL.,
Synthesis and Preclinical Evaluation of Radiolabeled [(103)Ru]BOLD-100., Pharmaceutics. 2023 Nov 15;15(11). pii: 2626. doi: 10.3390/pharmaceutics15112626.
Pfitzer, Lisa; Moser, Christina; Gegenfurtner, Florian; Arner, Anja; Foerster, Florian; Atzberger, Carina; Zisis, Themistoklis; Kubisch-Dohmen, Rebekka; Busse, Johanna; Smith, Rebecca,
Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy., Cell death & disease Vol.10, 2019
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM.,
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer., J Clin Invest. 2023 Dec 15;133(24). pii: e172503. doi: 10.1172/JCI172503.
Liu Y, Betori RC, Pagacz J, Frost GB, Efimova EV, Wu D, Wolfgeher DJ, Bryan TM, Cohen SB, Scheidt KA, Kron SJ.,
Targeting telomerase reverse transcriptase with the covalent inhibitor NU-1 confers immunogenic radiation sensitization, Cell Chem Biol. 2022 Oct 20;29(10):1517-1531.e7. doi: 10.1016/j.chembiol.2022.09.002. Epub 2022 Oct 6.
Gershoni A, Hassin O, Nataraj NB, Baruch S, Avioz-Seligman A, Pirona AC, Fellus-Alyagor L, Meir Salame T, Mukherjee S, Mallel G, Yarden Y, Aylon Y, Oren M.,
TAZ facilitates breast tumor growth by promoting an immune-suppressive tumor microenvironment., Mol Oncol. 2023 Dec;17(12):2675-2693. doi: 10.1002/1878-0261.13525. Epub 2023 Oct 16.
Gutwillig A, Santana-Magal N, Farhat-Younis L, Rasoulouniriana D, Madi A, Luxenburg C, Cohen J, Padmanabhan K, Shomron N, Shapira G, Gleiberman A, Parikh R, Levy C, Feinmesser M, Hershkovitz D, Zemser-Werner V, Zlotnik O, Kroon S, Hardt WD, Debets R, Reticker-Flynn NE, Rider P, Carmi Y.,
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy, Elife. 2022 Sep 20;11:e80315. doi: 10.7554/eLife.80315.
Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, Harwood SL, Alfonso C, Blanco B, Rubio-Pérez L, Jiménez-Reinoso A, Díez-Alonso L, Blanco FJ, Sanz L, Howard KA, Álvarez-Vallina L.,
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity, iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16.
Haake M, Haack B, Schaefer T, Harter PN, Mattavelli G, Eiring P, Vashist N, Wedekink F, Genssler S, Fischer B, Dahlhoff J, Mokhtari F, Kuzkina A, Welters MJP, Benz TM, Sorger L, Thiemann V, Almanzar G, Selle M, Thein K, Gonzalez MC, et al.,
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment., Nat Commun. 2023 Jul 20;14(1):4253. doi: 10.1038/s41467-023-39817-3.
Nguyen, O. N., Grimm, C., Schneider, L. S., Chao, Y. K., Atzberger, C., Bartel, K., . . . Vollmar, A. M. (2017),
Two-pore channel function is crucial for the migration of invasive cancer cells., Cancer Research, 77(6), 1427-1438. doi:10.1158/0008-5472.CAN-16-0852 [doi]
Allen KL, Cann J, Zhao W, Peterson N, Lazzaro M, Zhong H, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Tsui P, Li Q.,
Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models, PLoS One. 2020 Jun 4;15(6):e0234268. doi: 10.1371/journal.pone.0234268. eCollection 2020.
Rialdi A, Duffy M, Scopton AP, Fonseca F, Zhao JN, Schwarz M, Molina-Sanchez P, Mzoughi S, Arceci E, Abril-Fornaguera J, Meadows A, Ruiz de Galarreta M, Torre D, Reyes K, Lim YT, Rosemann F, Khan ZM, Mohammed K, Wang X, Yu X, Lakshmanan M, Rajarethinam R, et al.,
WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma., Nat Cancer. 2023 Aug;4(8):1157-1175. doi: 10.1038/s43018-023-00609-9. Epub 2023 Aug 3.